Abstract: Objective To explore the efficiency of postoperative individualized chemotherapy based on genetic testing results for non-small cell lung cancer (NSCLC). Methods Fifty-six NSCLC patients at stageⅡor ⅢA who accepted video- assisted thoracic operation were divided into two groups: the individualized chemotherapy group (n=26) and non individual⁃ ized chemotherapy group (n=30). The fresh lung tumor tissue of individualized chemotherapy group was tested target gene， in⁃ cluding excision repair cross complementing 1 (ERCC1)， ribonucleotide reductase subunit M1 (RRM1)， β-tubulin Ⅲ， thymi⁃ dylate synthase （TS)， epidermal growth factor receptor (EGFR) and breast cancer gene 1 (BRCA1). The theraputic plan was based on genetic testing results in individualized chemotherapy group, and the non individualized chemotherapy group re⁃ ceiving gemcitabine plus cisplatin. The 1-year disease free survival (DFS), 2-year disease free survival (DFS), the progres⁃ sion- free survival (PFS) and the overall survival (OS) were compared between two groups. Results The 2- year DFS (57.69%), PFS (22.1±5.0 months) and OS (24.1±3.2 months) were significantly higher in the individualized chemotherapy group than those of non individualized chemotherapy group (respectively 30.00%, 18.9±6.2 months, 21.9±4.3 months, P < 0.05). There was no significant difference in 1-year DFS between two groups (88.46% vs 83.33%, P < 0.05). Conclusion The individualized chemotherapy based on genetic testing results can enhance the 2-year DFS, PFS, OS and the efficiency of postoperative adjuvant chemotherapy for NSCLC.

Key words: carcinoma, non-small-cell lung, chemotherapy, adjuvant, disease-free survival, Kaplan-Meiers estimate, genetic testing, individualized chemotherapy